Diminished androgen levels are linked to irritable bowel syndrome and cause bowel dysfunction in mice

Introduction: Irritable bowel syndrome represents one of the most difficult gastroenterological diseases to treat, that usually induces the patients to follow different drug therapies, often not useful in symptom control. In this scenario low FODMAP diet could have positive effects in patients with irritable bowel syndrome, even because this type of diet regimen is characterized by a low gluten amount due to the exclusion of cereals. Methods: We enrolled 120 patients with irritable bowel syndrome, according to the Rome IV criteria, who were referred to Hepatogastroenterology Division of the University of Campania L. Vanvitelli from June to December 2018. They underwent a low FODMAP diet for six weeks, followed by a gradual weekly reintroduction of every category of food for three months. The patients had a follow-up evaluation for six months after the end of food reintroduction period. We measured abdominal pain with subjective numerical scale from 0 to 10. We evaluated other gastrointestinal symptoms with a questionnaire about symptoms of lower digestive tract, evaluating their frequency and intensity. We also evaluated the impact of irritable bowel syndrome on daily life with neurological bowel dysfunction score. Results: We obtained a good patient-adherence to diet and a statistically significant decrease of abdominal pain, bloating, flatulence, diarrhea, constipation, and neurological bowel dysfunction score (p < 0.001) at the end of the diet. These results remained constant in the follow-up period. Conclusions: We recommend the use of a low FODMAP diet regimen in patients with irritable bowel syndrome in order to control the symptoms and improve the quality of life.

Download Full-text

How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form.

Gut ◽

10.1136/gut.32.1.73 ◽

1991 ◽

Vol 32 (1) ◽

pp. 73-79 ◽

Cited By ~ 159

Author(s):

K W Heaton ◽

S Ghosh ◽

F E Braddon

Keyword(s):

Irritable Bowel Syndrome ◽

Bowel Dysfunction ◽

Controlled Study ◽

Stool Form ◽

Irritable Bowel ◽

Prospective Controlled Study

Download Full-text

Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients

Clinical Rheumatology ◽

10.1007/bf02229708 ◽

1996 ◽

Vol 15 (3) ◽

pp. 283-286 ◽

Cited By ~ 59

Author(s):

A. Sivri ◽

A. Cindaş ◽

F. Dinçer ◽

B. Sivri

Keyword(s):

Irritable Bowel Syndrome ◽

Bowel Dysfunction ◽

Irritable Bowel

Download Full-text

Childhood bladder and bowel dysfunction predicts irritable bowel syndrome phenotype in adult interstitial cystitis/bladder pain syndrome patients

Canadian Urological Association Journal ◽

10.5489/cuaj.4251 ◽

2017 ◽

Vol 11 (8) ◽

pp. 255-9 ◽

Cited By ~ 2

Author(s):

R. Christopher Doiron ◽

Barry A. Kogan ◽

Victoria Tolls ◽

Karen Irvine-Bird ◽

J. Curtis Nickel

Keyword(s):

Irritable Bowel Syndrome ◽

Interstitial Cystitis ◽

Bowel Movement ◽

Pain Syndrome ◽

Bowel Dysfunction ◽

Bladder Pain Syndrome ◽

The Other ◽

Bladder Pain ◽

History Of ◽

Irritable Bowel

Introduction: Many clinicians have suggested that a history of bladder and bowel dysfunction (BBD) in childhood predisposes to the development of interstitial cystitis/bladder pain syndrome (IC/BPS) or irritable bowel syndrome (IBS) in adulthood. We hypothesized that BBD symptoms in childhood would predict the IBS-associated phenotype in adult IC/BPS patients.Methods: Consecutive female patients (n=190) with a diagnosis of IC/BPS were administered a modified form of a clinical BBD questionnaire (BBDQ) to capture childhood BBD-like symptoms, as well as Interstitial Cystitis Symptoms Index (ICSI), Interstitial Cystitis Problem Index (ICPI), Pelvic Pain and Urgency/ Frequency (PUF) questionnaires and UPOINT categorization. Patients were stratified to IBS-positive or IBS-negative according to clinical assessment of IBS-like symptoms.Results: The 127 patients (67%) identified with IBS-like symptoms recalled significantly higher BBDQ scores than the 63 patients (33%) who were IBS-negative (2.8 vs. 2.3; p=0.05). The IBS-positive patients also reported a higher number of UPOINT domains than their non-IBS counterparts (3.8 vs. 2.9; p=0.0001), while their PUF total scores were significantly higher (13.6 vs. 12.3; p=0.04). IBSpositive patients more often recalled that in childhood they did not have a daily bowel movement (BM) (p=0.04) and had “to push for a BM” (p=0.009). In childhood, they “urinated only once or twice per day” (p=0.03) and recalled “painful urination” more than those without IBS (p=0.03). There were no significant differences between the groups in answers to the other five questions of the BBDQ.Conclusions: Our symptom recollection survey was able to predict the IBS phenotype of IC/BPS based on a childhood BBDQ. Further prospective studies are needed to further evaluate these novel findings.

Download Full-text

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction.

Gut ◽

10.1136/gut.33.6.825 ◽

1992 ◽

Vol 33 (6) ◽

pp. 825-830 ◽

Cited By ~ 275

Author(s):

W E Whitehead ◽

M D Crowell ◽

J C Robinson ◽

B R Heller ◽

M M Schuster

Keyword(s):

Irritable Bowel Syndrome ◽

Life Events ◽

Stressful Life Events ◽

Bowel Dysfunction ◽

Stressful Life ◽

Bowel Symptoms ◽

Irritable Bowel

Download Full-text

Candidate genes and sensory functions in health and irritable bowel syndrome

AJP Gastrointestinal and Liver Physiology ◽

10.1152/ajpgi.90202.2008 ◽

2008 ◽

Vol 295 (2) ◽

pp. G219-G225 ◽

Cited By ~ 43

Author(s):

Michael Camilleri ◽

Irene Busciglio ◽

Paula Carlson ◽

Sanna McKinzie ◽

Duane Burton ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Bowel Function ◽

Bowel Dysfunction ◽

Gastric Volume ◽

Genetic Variations ◽

Colonic Transit ◽

Pain Sensation ◽

Rectal Compliance ◽

Pain Ratings ◽

Irritable Bowel

Adrenergic and serotonergic (ADR-SER) mechanisms alter gut (GI) function; these effects are mediated through G protein transduction. Candidate genetic variations in ADR-SER were significantly associated with somatic scores in irritable bowel syndrome (IBS) and gastric emptying but not small bowel or colonic transit. Our aim was to assess whether candidate ADR-SER genes are associated with motor and sensory GI functions in IBS and subgroups on the basis of bowel dysfunction. In 122 patients with IBS and 39 healthy controls, we assessed gastrointestinal somatic symptoms and affect by validated questionnaires. We measured: gastric volume (GV), maximum tolerated volume, rectal compliance, sensation thresholds and ratings, and genetic variations including α 2A (C-1291G), α 2C (Del 332–325), GNβ 3 (C825T), and 5-HTTLPR. Demographics and genotype distributions were similar in the patients with IBS subgrouped on bowel function. There were significant associations between 5-HTTLPR SS genotype and absence of IBS symptoms and between 5-HTTLPR LS/SS genotype and increased rectal compliance and increased pain ratings, particularly at 12 and 24 mmHg distensions. GNβ 3 was associated only with fasting GV; we did not detect associations between α 2A genotype and the gastrointestinal sensory or motor functions tested. We concluded that 5-HTTLPR LS/SS genotype is associated with both increased pain sensation and increased rectal compliance though the latter effect is unlikely to contribute to increased pain sensation ratings with LS/SS genotype. The data suggest the hypotheses that the endophenotype of visceral hypersensitivity in IBS may be partly related to genetic factors, and the association of GNβ 3 with fasting GV may explain, in part, the reported association of GNβ 3 with dyspepsia.

Download Full-text

Adherence to Short-course Pharmacotherapy in Adults with Irritable Bowel Syndrome

Western Journal of Nursing Research ◽

10.1177/0193945919872419 ◽

2019 ◽

Vol 42 (7) ◽

pp. 524-534 ◽

Cited By ~ 2

Author(s):

LeeAnne B. Sherwin ◽

Chelsea B. Deroche ◽

Poungkamon Krisanabud ◽

Michelle Matteson-Kome ◽

Matthew Bechtold ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Psychological Distress ◽

Perceived Stress ◽

Bowel Dysfunction ◽

Future Research ◽

Patient Centered ◽

Childhood Experiences ◽

Adherence Data ◽

Lower Pain ◽

Irritable Bowel

Irritable Bowel Syndrome (IBS), characterized by abdominal pain and bowel dysfunction, treatment focuses on alleviating symptoms. Adherence is crucial for pharmacologic management success. We examined 73 adult’s objective adherence to rifaximin using the taxonomy for adherence. Demographic, quality of life (QOL), psychological distress, perceived stress, adverse childhood experiences (ACE), pain, and adherence data were collected. Impaired QOL, elevated psychological distress and perceived stress, and a significant number of ACE were reported at baseline. Average time to prescription initiation was 2.5 days. Once implemented, 92% missed midday dose and persisted 5 days beyond the prescribed dose. High-adherers reported lower pain levels post-rifaximin compared to low-adherers. Objective adherence was significantly lower than self-reported. Objective adherence was not predicted by above variables. Adherence to rifaximin is poor in those with IBS. Future research examining perceived barriers/facilitators toward rifaximin adherence may provide insight into patient-centered, modifiable targets for adherence interventions and improve patient-related outcomes.

Download Full-text

Irritable bowel syndrome: the problem and the problem of treating it – is there a role for probiotics?

Proceedings of The Nutrition Society ◽

10.1017/s0029665114000706 ◽

2014 ◽

Vol 73 (4) ◽

pp. 470-476 ◽

Cited By ~ 6

Author(s):

Antonieta R. Santos ◽

P. J. Whorwell

Keyword(s):

Irritable Bowel Syndrome ◽

Therapeutic Potential ◽

Medical Profession ◽

Treatment Options ◽

Bowel Dysfunction ◽

Poor Quality ◽

New Treatment ◽

Irritable Bowel ◽

Different Strains ◽

The Impact

The aim of this review is to highlight the impact of irritable bowel syndrome (IBS) in those patients who consult the medical profession and examine the therapeutic potential of probiotics in this condition, where there is a strong need for new treatment options. Traditionally, IBS is frequently regarded as a trivial condition which is certainly not life threatening and mainly psychological in origin. However, these preconceptions are misplaced, as in some patients the condition can be devastating with the pain being as severe as that of childbirth coupled with incapacitating bowel dysfunction. In addition, patients suffer from a variety of non-colonic symptoms such as low backache, constant lethargy, nausea and genito-urinary problems, all of which lead to these patients having extremely poor quality of life. Unfortunately, the treatment of IBS is very unsatisfactory with only one new medication being developed for this condition in the last 25 years. It is now recognised that IBS is a multifactorial condition with symptoms being triggered by a variety of factors, some of which appear to be influenced by probiotics, resulting in speculation that they may have therapeutic potential in this condition. There have been over thirty controlled clinical trials of probiotics in IBS with approximately two-thirds of these studies showing evidence of an improvement in symptoms. However, not all probiotics appear to be effective with different symptoms being improved by different strains and some improving symptoms more than others. Consequently, the ideal probiotic for the treatment of IBS has yet to be defined, but the evidence is good enough to encourage further research with the aim of identifying an optimal strain or strains.

Download Full-text